브린졸라미드 복합제의 개방각 녹내장 또는 고안압증에 대한 효과 및 안전성 검증: 체계적 문헌 고찰 및 메타분석 연구 (Effectiveness and Safety Verification of Brinzolamide Combination Therapy on Primary Open-angle Glaucoma or Ocular Hypertension: A Systematic Review and Meta-analysis Study)

서지정보

· 발행기관 : 한국임상약학회
· 수록지 정보 : 한국임상약학회지 / 31권 / 3호 / 205 ~ 215페이지
· 저자명 : 김진아, 이희영

초록

Background: The treatment of primary open-angle glaucoma (POAG) or ocular hypertension (OHT) for intraocular pressure (IOP)reduction is recommended to proceed with the use of the compound. Therefore, this study aimed to evaluate the efficacy and safetyof brinzolamide combination therapy on POAG and OHT following the subgroup analysis among types of brinzolamide combinedmedications. Methods: By June 2019, PubMed, EMBASE and Cochrane Library were searched to find a study that met our inclusioncriteria. Based on randomized control trials (RCTs), we collected studies that tested the brinzolamide combination therapy in POAGand OHT patients, and analyzed the literature identified by the results of the study on IOP reduction and adverse reactions. Results: Atotal of 13 literature was collected to conduct an analysis including 2,197 patients. The intervention included brinzolamidecombination therapies, combined with timolol, brimonidine, PGA or combined with both brimonidine and PGA. The analysisshowed significant decreasing tendency for values at morning and end treatment per day in the use of brinzolamide combinationtherapy in the absolute IOP change (mean difference (MD) −1.41; 95% CI −1.92, −0.90; p<0.001 vs. MD −1.46; 95% CI −2.03,−0.89; p<0.00001, respectively). We could see higher adverse reactions in the brinzolamide combination group using intervention(odds ratio 1.43; 95% CI 1.20, 1.71; p<0.0001). Conclusion: Regarding IOP reduction in POAG and OHT patients, brinzolamidecombination therapy is more effective but less safe than control treatment, which diverse among types of combined medications.
Thus, more individualized therapy should be applied in real-world practice.

영어초록

Background: The treatment of primary open-angle glaucoma (POAG) or ocular hypertension (OHT) for intraocular pressure (IOP)reduction is recommended to proceed with the use of the compound. Therefore, this study aimed to evaluate the efficacy and safetyof brinzolamide combination therapy on POAG and OHT following the subgroup analysis among types of brinzolamide combinedmedications. Methods: By June 2019, PubMed, EMBASE and Cochrane Library were searched to find a study that met our inclusioncriteria. Based on randomized control trials (RCTs), we collected studies that tested the brinzolamide combination therapy in POAGand OHT patients, and analyzed the literature identified by the results of the study on IOP reduction and adverse reactions. Results: Atotal of 13 literature was collected to conduct an analysis including 2,197 patients. The intervention included brinzolamidecombination therapies, combined with timolol, brimonidine, PGA or combined with both brimonidine and PGA. The analysisshowed significant decreasing tendency for values at morning and end treatment per day in the use of brinzolamide combinationtherapy in the absolute IOP change (mean difference (MD) −1.41; 95% CI −1.92, −0.90; p<0.001 vs. MD −1.46; 95% CI −2.03,−0.89; p<0.00001, respectively). We could see higher adverse reactions in the brinzolamide combination group using intervention(odds ratio 1.43; 95% CI 1.20, 1.71; p<0.0001). Conclusion: Regarding IOP reduction in POAG and OHT patients, brinzolamidecombination therapy is more effective but less safe than control treatment, which diverse among types of combined medications.
Thus, more individualized therapy should be applied in real-world practice.

참고자료

· 없음